TNF and colitis: IBD patients show decreased rates of A. muciniphila [165, 166] and, in the mice models of colitis, the administration of A. muciniphila improves intestinal permeability [167], decreases colon inflammation and the expression of pro-inflammatory cytokines (TNF-α, IFN-γ) [168].